Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, is being sued for “unlawfully” delaying generic competition to Zytiga, its branded cancer medication.
The US Court of Appeals for the Federal Circuit has delivered a blow to Nuvo Pharmaceuticals by reversing a decision which had upheld the validity of the Canadian company’s pain relief drug Vimovo.
The European Union has adopted the proposed supplementary protection certificate manufacturing waiver, despite criticism from parts of the pharmaceutical industry.
The US Court of Appeals for the Federal Circuit delivered a blow to Johnson & Johnson on Tuesday, May 14, by confirming the invalidation of a patent covering blockbuster prostate cancer drug Zytiga.
Boehringer Ingelheim has become the latest biosimilar maker to resolve litigation over AbbVie’s arthritis treatment Humira.
44 US states have filed a joint complaint against 20 drug companies, alleging they engaged in illegal conspiracies to “manipulate prices, reduce competition” and restrain trade for more than 100 generic drugs.
Elkington + Fife has unveiled Mark Scott as a new partner in the UK firm’s patent practice.
The US Court of Appeals for the Federal Circuit yesterday, May 8, rejected an appeal from Amgen in patent litigation relating to two Sandoz biosimilars.
A generic version of Gilead’s Truvada will hit the market in 2020, a year earlier than expected.
The US Court of Appeals for the Federal Circuit affirmed a series of Patent Trial and Appeal Board inter partes reviews, which upheld a patent owned by Eli Lilly late last week.